Closing Gaps in Care: Health Equity and the US Inflation Reduction Act – A Cutting- Edge Conversation 

The US Inflation Reduction Act (US IRA) of 2022 introduced major reforms to drug pricing and Medicare negotiations—initiatives aimed at reducing costs but with consequences that reach well beyond economic considerations. These shifts prompted key questions. 

• How would new pricing policies affect access for underrepresented communities?  
• Would value-based care models narrow disparities or risk widening them? 

In this HealthEconomics.com webinar, Haripriya Jain, MS, MBA, executive director of health economics and market access, PPD clinical research business of Thermo Fisher Scientific,  and other panelists , explore: 

• How policy shifts under the US IRA intersect with health equity. 
• The impact of the US IRA on drug pricing, evidence planning and access. 
• The strategies stakeholders can use to promote fairness in access and affordability.